TABLE 3.

CFR for fosfomycin and meropenem against non-MBL and MBL-producing P. aeruginosa clinical isolates by dosing regimens in monotherapy and combination therapy^a

Antimicrobial and regimen	Total daily dose (g)	CFR (%)
		Monotherapy	Combination therapy
Fosfomycin
4 g i.v. q8h	12	11	81
4 g i.v. q6h	16	17	86
6 g i.v. q8h	18	22	88
8 g i.v. q8h	24	33	91
Meropenem (0.5-h infusion)
1 g q8h	3	53	72
1.5 g q6h	6	63	79
2 g q8h	6	62	79
Meropenem (3-h infusion)
1 g q8h	3	56	73
1.5 g q6h	6	65	80
2 g q8h	6	64	80

^aThe pharmacodynamic surrogate index for fosfomycin was an fAUC/MIC of 40.8 for a CL_CR of >40 ml/min, and that for meropenem was an ƒT_>MIC of 40% for a CL_CR of >50 ml/min.